Georgia's Online Cancer Information Center

Find A Clinical Trial

Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors

Status
Active
Cancer Type
Breast Cancer
Gynecologic Cancers
Ovarian Cancer
Primary Peritoneal Cancer
Prostate Cancer
Solid Tumor
Unknown Primary
Trial Phase
Phase I
Eligibility
18 Years and older, Male and Female
Study Type
Treatment
NCT ID
NCT04726332
Protocol IDs
XL102-101 (primary)
NCI-2021-03620
Study Sponsor
Exelixis Inc

Summary

This is a Phase 1, open-label, dose-escalation and expansion study evaluating the safety,
tolerability, PK, antitumor activity, and effect on biomarkers of XL102 administered orally
alone and in multiple combination regimens to subjects with advanced solid tumors.

Eligibility

  1. Cytologically or histologically and radiologically confirmed solid tumor that is inoperable, locally advanced, metastatic, or recurrent.
  2. Dose-Escalation Stage Cohort A (Solid Tumors): The subject has a solid tumor that is unresectable or metastatic and for which life-prolonging measures do not exist or available therapies are intolerable or no longer effective.
  3. Dose-Escalation Stage Cohort B and Cohort-Expansion Stage Cohorts F and H (Hormone Receptor-Positive Breast Cancer): Subjects with breast cancer that is hormone receptor-positive (estrogen receptor positive [ER+] and/or progesterone receptor positive [PR+]) and negative for human epidermal growth factor receptor 2 (HER-2 negative [HER-2-]) and who have documented radiographic disease progression during or following their last systemic anticancer therapy for inoperable locally advanced or metastatic disease.
  4. Dose-Escalation Stage Cohort C and Cohort-Expansion Stage Cohorts G and I (Metastatic Castration-Resistant Prostate Cancer): Subjects with adenocarcinoma of the prostate. Note: Neuroendocrine differentiation and other histological features are permitted if adenocarcinoma is the primary histology.
  5. Cohort-Expansion Stage Cohort D (Triple Negative Breast Cancer): Subjects with breast cancer that is negative for HER-2, estrogen receptors, and progesterone receptors, and who have documented radiographic disease progression during or following their last systemic anticancer therapy for inoperable locally advanced or metastatic disease.
  6. Cohort-Expansion Stage Cohort E (Epithelial Ovarian Cancer): Subjects with epithelial ovarian cancer, including primary peritoneal cancer (PPC) and fallopian tube cancer (FTC) who have platinum-resistant disease following treatment with a platinum-containing chemotherapy. Ovarian borderline epithelial tumors (low malignant potential) are excluded.
  7. Expansion Cohorts: Subjects must have measurable disease per RECIST 1.1 as determined by the Investigator.
  8. Tumor tissue material (archival or fresh tumor tissue [if it can be safely obtained]).
  9. Recovery to baseline or = Grade 1 severity (Common Terminology Criteria for Adverse Events version 5 [CTCAE v5]) from AEs.
  10. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.
  11. Adequate organ and marrow function.
  12. Sexually active fertile subjects and their partners must agree to use medically accepted methods of contraception.
  13. Female subjects of childbearing potential must not be pregnant at screening.
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a statewide nonprofit that leverages partnerships and innovation to attract more clinical trials, increase research, and promote education and early detection to improve cancer care for Georgians in rural, urban, and suburban communities across the state.